Stock Track | Hims & Hers Health Plummets 5.10% Intraday Amid Patent Lawsuit from Novo Nordisk and Regulatory Scrutiny

Stock Track

02/10

Hims & Hers Health Inc. (HIMS) stock plummeted 5.10% during intraday trading on Tuesday, extending recent losses as the telehealth company faces a patent infringement lawsuit from Novo Nordisk and regulatory pressure over its compounded weight-loss drug.

The decline follows Novo Nordisk's lawsuit filed on Monday, alleging that Hims infringed patents for semaglutide, the active ingredient in Novo's blockbuster weight-loss drug Wegovy. Hims had launched a $49 compounded version of the medication last week but reversed the launch over the weekend after legal threats from Novo and scrutiny from the U.S. Food and Drug Administration.

Analysts have responded by cutting price targets on Hims shares, citing increased legal risks. Deutsche Bank reduced its target to $31 from $42, while Canaccord Genuity slashed its target to $30 from $68, though maintaining a Buy rating on the stock. The legal battle represents a significant challenge for Hims as it expands in the weight-loss market.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1177836469"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177836469\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177836469?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 23:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177836469","market":"nz","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Plummets 5.10% Intraday Amid Patent Lawsuit from Novo Nordisk and Regulatory Scrutiny","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) stock plummeted 5.10% during intraday trading on Tuesday, extending recent losses as the telehealth company faces a patent infringement lawsuit from Novo Nordisk and regulatory pressure over its compounded weight-loss drug.</p><p>The decline follows Novo Nordisk's lawsuit filed on Monday, alleging that Hims infringed patents for semaglutide, the active ingredient in Novo's blockbuster weight-loss drug Wegovy. Hims had launched a $49 compounded version of the medication last week but reversed the launch over the weekend after legal threats from Novo and scrutiny from the U.S. Food and Drug Administration.</p><p>Analysts have responded by cutting price targets on Hims shares, citing increased legal risks. Deutsche Bank reduced its target to $31 from $42, while Canaccord Genuity slashed its target to $30 from $68, though maintaining a Buy rating on the stock. The legal battle represents a significant challenge for Hims as it expands in the weight-loss market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Plummets 5.10% Intraday Amid Patent Lawsuit from Novo Nordisk and Regulatory Scrutiny</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Plummets 5.10% Intraday Amid Patent Lawsuit from Novo Nordisk and Regulatory Scrutiny\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-02-10 23:24</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) stock plummeted 5.10% during intraday trading on Tuesday, extending recent losses as the telehealth company faces a patent infringement lawsuit from Novo Nordisk and regulatory pressure over its compounded weight-loss drug.</p><p>The decline follows Novo Nordisk's lawsuit filed on Monday, alleging that Hims infringed patents for semaglutide, the active ingredient in Novo's blockbuster weight-loss drug Wegovy. Hims had launched a $49 compounded version of the medication last week but reversed the launch over the weekend after legal threats from Novo and scrutiny from the U.S. Food and Drug Administration.</p><p>Analysts have responded by cutting price targets on Hims shares, citing increased legal risks. Deutsche Bank reduced its target to $31 from $42, while Canaccord Genuity slashed its target to $30 from $68, though maintaining a Buy rating on the stock. The legal battle represents a significant challenge for Hims as it expands in the weight-loss market.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1177836469","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177836469","pubTimestamp":1770737085,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) stock plummeted 5.10% during intraday trading on Tuesday, extending recent losses as the telehealth company faces a patent infringement lawsuit from Novo Nordisk and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"个股追踪|Hims&Hers Health盘中暴跌5.10%，遭诺和诺德专利诉讼及监管审查","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) stock plummeted 5.10% during intraday trading on Tuesday, extending recent losses as the telehealth company faces a patent infringement lawsuit from Novo Nordisk and regulatory pressure over its compounded weight-loss drug.The decline follows Novo Nordisk's lawsuit filed on Monday, alleging that Hims infringed patents for semaglutide, the active ingredient in Novo's blockbuster weight-loss drug Wegovy. Hims had launched a $49 compounded version of the medication last week but reversed the launch over the weekend after legal threats from Novo and scrutiny from the U.S. Food and Drug Administration.Analysts have responded by cutting price targets on Hims shares, citing increased legal risks. Deutsche Bank reduced its target to $31 from $42, while Canaccord Genuity slashed its target to $30 from $68, though maintaining a Buy rating on the stock. The legal battle represents a significant challenge for Hims as it expands in the weight-loss market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}